There is no single best medicine for rheumatoid arthritis, but methotrexate is the universal starting point for nearly every patient. It has been the cornerstone of RA treatment for decades, and the most recent 2025 EULAR guidelines still recommend it as the first medication to try, ideally paired with a short course of steroids to control inflammation while it takes effect. What comes next depends on how your body responds over the first three to six months.
Why Methotrexate Comes First
Methotrexate belongs to a class of drugs called disease-modifying antirheumatic drugs (DMARDs), meaning it doesn’t just mask pain. It slows the immune system’s attack on your joints, which is what actually prevents long-term damage. The typical starting dose is 7.5 mg taken once a week, usually as a pill, though some people switch to injections if they get nausea. Your doctor will gradually increase the dose based on your response, sometimes up to 20 mg per week or higher.
You won’t feel results right away. Methotrexate takes about four to six weeks to start working, and you may need several dose adjustments, each requiring another four to six weeks to evaluate. A full trial of three to six months at an adequate dose is standard before anyone considers the drug a failure. During that ramp-up period, a short course of corticosteroids (like prednisone) often bridges the gap, bringing rapid relief within days while the methotrexate builds up in your system.
Most people tolerate methotrexate well, but it does require regular blood monitoring. When you first start or change your dose, expect blood draws every two weeks for at least six weeks, then monthly for up to a year. Once you’re stable, testing drops to roughly every 12 weeks. These labs check your blood cell counts, liver function, and kidney function, since methotrexate can stress both organs over time. You’ll also take folic acid alongside it, which significantly reduces side effects like mouth sores and nausea.
What Happens If Methotrexate Isn’t Enough
If methotrexate alone doesn’t bring your disease under adequate control within three to six months, the next step is adding a biologic DMARD. These are injectable or infused medications that target specific parts of the immune system rather than suppressing it broadly. The most commonly used first-line biologics are TNF inhibitors, which block a protein called tumor necrosis factor that drives joint inflammation. You typically stay on methotrexate at the same time, since the combination works better than either drug alone.
TNF inhibitors can work fast. Some people notice improvements within two to four weeks, with continued gains over three to six months. A Cochrane review found that combining methotrexate with a TNF inhibitor was statistically better at preventing joint damage in newly diagnosed patients compared to methotrexate alone, though the actual difference in joint erosion over one year was small. The real benefit is in controlling symptoms and preserving function over the long haul.
If a TNF inhibitor doesn’t work or stops working, your rheumatologist has several other biologic options that target different immune pathways. Some block a protein involved in activating immune cells, others deplete a specific type of white blood cell, and others target inflammatory signaling molecules. These alternatives typically take a bit longer to kick in, anywhere from four weeks to three months depending on the drug.
Where JAK Inhibitors Fit In
JAK inhibitors are a newer class of pills that work differently from biologics. Instead of blocking a single immune protein, they interfere with signaling pathways inside immune cells that drive inflammation. They tend to act quickly, sometimes showing measurable improvement within the first two weeks.
Recent data from a Japanese registry found that patients who switched from one JAK inhibitor to another achieved remission at dramatically higher rates than those who switched to a biologic: 38.7% versus 2.2% at six months. Disease activity scores were also significantly lower in the JAK inhibitor group as early as two weeks after switching. This suggests that for patients whose bodies respond well to this drug class, staying within it can be more effective than changing approaches entirely.
However, JAK inhibitors carry serious safety concerns that keep them from being first-choice medications. The FDA requires its strongest warning label on all JAK inhibitors approved for RA, based on a large safety trial that compared one of these drugs head-to-head with TNF inhibitors. That trial found higher rates of heart attacks, strokes, blood clots, cancer (particularly lymphoma and lung cancer), and death in patients taking the JAK inhibitor. The increased cancer risk was roughly 48% higher compared to TNF inhibitors. Because of these findings, JAK inhibitors are currently limited to patients who haven’t responded to or can’t tolerate at least one TNF inhibitor.
Other DMARDs You May Be Offered
Not everyone can take methotrexate. For those patients, rheumatologists turn to other conventional DMARDs, each with its own timeline and profile.
- Hydroxychloroquine is the mildest option, often used for very early or mild RA. It takes two to four months to show results and is sometimes combined with other DMARDs rather than used alone.
- Sulfasalazine works within six weeks to three months. It’s frequently used in combination with methotrexate and hydroxychloroquine in what’s called “triple therapy.”
- Leflunomide is the closest alternative to methotrexate in terms of potency, with a relatively fast onset of four to eight weeks. It requires the same kind of liver monitoring.
These medications are genuinely useful, but none matches methotrexate’s track record as a solo agent for moderate-to-severe disease. They’re most effective when combined with each other or with methotrexate.
The Cost Factor
Methotrexate is inexpensive, costing a fraction of what newer treatments run. That’s part of why it remains the first-line drug worldwide. Biologic DMARDs are a different story entirely: originator products typically cost over $80,000 per year in the United States and over £10,000 per year in the UK. Biosimilars, which are near-identical copies of biologics, have brought prices down in some markets, though the savings vary widely depending on your country and insurance coverage.
JAK inhibitors, being pills rather than injections, are cheaper to manufacture than biologics but still expensive at retail. Generic versions of some JAK inhibitors are already available in countries like India and Bangladesh at less than 1% of the originator cost, though these aren’t yet available in most Western markets.
How Treatment Decisions Actually Work
RA treatment follows a “treat-to-target” strategy. Your rheumatologist sets a specific goal, usually remission or at least low disease activity, and adjusts medications every three to six months until you reach it. This means your treatment plan isn’t static. You’ll likely try methotrexate first, possibly add a biologic if needed, and potentially switch between biologics or try a JAK inhibitor if earlier options fail.
The best medicine for your RA is ultimately the one that gets your disease under control with side effects you can live with. For most people, that journey starts with methotrexate. For many, it also ends there. A significant number of patients achieve low disease activity or remission on methotrexate alone or in combination with another conventional DMARD, and never need a biologic at all. For those who do need to escalate, the options are broader and more effective than at any point in the history of treating this disease.